Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555492 | 0.79 | KMT2A (0.35) | PDE10AKMT2ARPS6KA5KDM4E | |
| SCHEMBL2015390 | 0.76 | KMT2A (0.47) | KMT2ARPS6KA5SMN1; SMN2ALDH1A1 | |
| SCHEMBL16566107 | 0.76 | ABL1 (0.36) | KMT2ARPS6KA5 | |
| SCHEMBL18031198 | 0.76 | HRH2 (0.41) | — | |
| SCHEMBL14672723 | 0.76 | CYP3A4 (0.33) | — | |
| SCHEMBL14672722 | 0.76 | CYP3A4 (0.33) | — | |
| SCHEMBL25283172 | 0.76 | ALDH1A1 (0.46) | PDE10AKMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL25778753 | 0.73 | CYP1A2 (0.39) | PDE10AKMT2AALDH1A1 | |
| SCHEMBL20555325 | 0.72 | KMT2A (0.37) | KMT2ARPS6KA5AXL | |
| SCHEMBL21158071 | 0.72 | CSNK1A1 (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103864770-B | Aminopyrimidine and pyridyl amine inhibitor as Hedgehog signal transduction | 江苏先声药业有限公司 | 2019-06-11 | — | — | CN | disclosed |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | VITAE PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9707232-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170007603-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-9416135-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160113930-A1 | COMPOUNDS FOR USE IN TREATING RETT SYNDROME | VITAE PHARMACEUTICALS, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20150336963-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-11-26 | — | — | US | disclosed |
| US-20150250787-A1 | COMPOUNDS FOR USE IN TREATING SKIN CANCERS | VITAE PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9073931-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150065515-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | PDE10A 1443/4885KMT2A 3622/4885RPS6KA5 2253/4885 |
| US-20150336963-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | PDE10A 1443/4885KMT2A 3622/4885RPS6KA5 2253/4885 |
| US-20170231992-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | PDE10A 156/4885KMT2A 4716/4885RPS6KA5 1893/4885 |
| US-20150065515-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | PDE10A 1443/4885KMT2A 3622/4885RPS6KA5 2253/4885 |
| US-20160113930-A1 | COMPOUNDS FOR USE IN TREATING RETT SYNDROME | RET, RARS2, RARS1 | PDE10A 70/4885KMT2A 515/4885RPS6KA5 2444/4885 |
| US-20150250787-A1 | COMPOUNDS FOR USE IN TREATING SKIN CANCERS | TP53, KRT18, VHL | PDE10A 3665/4885KMT2A 2452/4885RPS6KA5 1974/4885 |
| US-20180133220-A1 | COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS | TNNI3, FABP3, TNNT2 | PDE10A 156/4885KMT2A 4716/4885RPS6KA5 1893/4885 |
| US-20170007603-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | PDE10A 1443/4885KMT2A 3622/4885RPS6KA5 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.